Is VINCU or QYLD a better dividend investment in 2026?

VINCU currently yields 7.41% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: QYLD offers higher current income.

What is the dividend yield difference between VINCU and QYLD?

VINCU has a forward dividend yield of 7.41% ($2.00/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 4.51 percentage points.

Home › Compare › VINCU vs QYLD

VINCU vs QYLD: Dividend Comparison 2026

VINCU yields 7.41% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 VINCU wins by $7.3K in total portfolio value

INVESTMENT

TIME HORIZON10 years

VINCU

● Live price

7.41%

Share price

$27.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$32.7K

Annual income

$1,184.90

Full VINCU calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — VINCU vs QYLD

📍 VINCU pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	VINCU	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, VINCU + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

VINCU pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VINCU

Annual income on $10K today (after 15% tax)

$629.63/yr

After 10yr DRIP, annual income (after tax)

$1,007.17/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, QYLD beats the other by $3,803.25/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VINCU + QYLD for your $10,000?

VINCU: 50%QYLD: 50%

100% QYLD50/50100% VINCU

Portfolio after 10yr

$29.0K

Annual income

$3,422.11/yr

Blended yield

11.79%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VINCU buys

QYLD buys

No recent congressional trades found for VINCU or QYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricVINCUQYLD

Forward yield	7.41%	11.92% ✓
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$32.7K ✓	$25.4K
Annual income after 10y	$1,184.90	$5,659.31 ✓
Total dividends collected	$9.7K	$27.1K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: VINCU vs QYLD ($10,000, DRIP)

Year	VINCU Portfolio	VINCU Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1← crossover	$11,441	$740.74	$10,352	$1,192.36	+$1.1K → VINCU
2	$13,034	$792.02	$10,830	$1,347.57	+$2.2K → VINCU
3	$14,789	$843.26	$11,460	$1,539.07	+$3.3K → VINCU
4	$16,719	$894.25	$12,275	$1,777.84	+$4.4K → VINCU
5	$18,834	$944.79	$13,323	$2,078.95	+$5.5K → VINCU
6	$21,147	$994.69	$14,667	$2,463.34	+$6.5K → VINCU
7	$23,671	$1,043.78	$16,396	$2,960.57	+$7.3K → VINCU
8	$26,420	$1,091.93	$18,631	$3,612.97	+$7.8K → VINCU
9	$29,408	$1,139.01	$21,548	$4,482.15	+$7.9K → VINCU
10	$32,652	$1,184.90	$25,398	$5,659.31	+$7.3K → VINCU

VINCU vs QYLD: Complete Analysis 2026

VINCU — Stock

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.

Full VINCU Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this VINCU vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VINCU vs SCHD VINCU vs JEPI VINCU vs O VINCU vs KO VINCU vs MAIN VINCU vs XYLD VINCU vs JEPQ VINCU vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.